Search clinical trials for: trabedersen

Total 6 results

Isarna Therapeutics GmbH

Completed

Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2

Melanoma | Colorectal Neoplasms | Pancreatic Neoplasms

Germany
Korea United Pharm. Inc.

Terminated

Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis (CASIS)

Acute Sinusitis
Isarna Therapeutics GmbH

Terminated

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma (SAPPHIRE)

Glioblastoma | Anaplastic Astrocytoma

Spain, Taiwan, Korea, Republic of, United States, Hungary, Germany, Argentina, Brazil, India, Canada, Austria, France, Mexico, Poland, Russian Federation, United Kingdom
Oncotelic Inc.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

COVID-19

Brazil
University of Washington
Genentech, Inc.; Oncotelic Therapeutics, Inc.

Withdrawn

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Isarna Therapeutics GmbH

Completed

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Glioblastoma | Anaplastic Astrocytoma

Germany, Austria, Georgia, India, Israel, Russian Federation

3

Subscribe